Literature DB >> 10334266

Detection of ErbB2 oversignalling in a majority of breast cancers with phosphorylation-state-specific antibodies.

X Ouyang, T Gulliford, A Doherty, G C Huang, R J Epstein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10334266     DOI： 10.1016/S0140-6736(99)01095-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

1.  Extracting functional information from tissues.

Authors:  M P DiGiovanna
Journal:  Mol Diagn       Date:  2001-03

Review 2.  Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology.

Authors:  James W Mandell
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

3.  The antibody sc-33040-R fails to specifically recognize phosphorylation of ErbB4 on tyrosine1056.

Authors:  Richard M Gallo; David J Riese
Journal:  Growth Factors       Date:  2007-10       Impact factor: 2.511

4.  Association of ErbB2 Ser1113 phosphorylation with epidermal growth factor receptor co-expression and poor prognosis in human breast cancer.

Authors:  X Ouyang; T Gulliford; H Zhang; G Smith; G Huang; R J Epstein
Journal:  Mol Cell Biochem       Date:  2001-02       Impact factor: 3.396

5.  Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleration in human breast cancer cells.

Authors:  G C Huang; S Hobbs; M Walton; R J Epstein
Journal:  Br J Cancer       Date:  2002-04-08       Impact factor: 7.640

6.  Non-phosphorylated Tyr-1248 form of human epidermal growth factor receptor 2 (HER2) predicts resistance to trastuzumab therapy and poor disease-free survival of HER2-positive breast cancer patients.

Authors:  Snježana Ramić; Frane Paić; Velda Smajlbegović; Melita Perić Balja; Lea Hiršl; Ingrid Marton; Fabijan Knežević
Journal:  Croat Med J       Date:  2022-04-30       Impact factor: 2.415
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.